Back to Agenda
Start–Ups Meet Regulatory and Industry – How Can Ideas from Academia Be Best Translated to Novel Treatment Options? What Kind of Partnerships Are Required?
Session Chair(s)
Michael Brandkamp
Managing Director, High-Tech Gruenderfonds, Germany
Young biotech companies are faced with a plethora of challenges nowadays. Not only do they have to find the money to pursue their research, but also to navigate in an increasingly complex regulatory environment. The panel will discuss what partnerships are required to successfully translate disruptive novel ideas into novel treatment options
Speaker(s)
Melanie Carr
Head of Stakeholders and Communication Division, European Medicines Agency, Netherlands
Presentation
Andreas Schmidt, DRSc
CEO, AYOXXA Biosystems, Germany
Ulrich Dauer, DRSc
CEO, OMEICOS, Germany
New Treatment Paradigms – Regulatory Challenges for SMEs
Sam Wadsworth, PhD
Chief Scientific Officer, Dimension Therapeutics, United States
Presentation
Frank Kalkbrenner
Corporate Vice President, Boehringer Ingelheim Venture Fund, Germany
The Role of Venture Funds in Enabling Innovation
Joseph Scheeren, PharmD
Founder, Scheeren HealthCare LLC, United States
The Role of Industry in the Innovation Ecosystem
Have an account?